FIL Ltd Raises Holdings in Stryker Co. (NYSE:SYK)

FIL Ltd increased its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 1.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 570,499 shares of the medical technology company's stock after acquiring an additional 9,697 shares during the quarter. FIL Ltd owned approximately 0.15% of Stryker worth $205,408,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Stryker by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock worth $11,773,213,000 after buying an additional 252,188 shares during the last quarter. FMR LLC raised its position in Stryker by 10.0% in the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock worth $2,892,946,000 after acquiring an additional 727,850 shares during the period. Geode Capital Management LLC boosted its stake in Stryker by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock valued at $2,539,033,000 after acquiring an additional 168,436 shares during the last quarter. Norges Bank bought a new position in shares of Stryker during the 4th quarter valued at approximately $1,710,744,000. Finally, Invesco Ltd. increased its stake in shares of Stryker by 15.3% during the 4th quarter. Invesco Ltd. now owns 2,007,105 shares of the medical technology company's stock worth $722,658,000 after purchasing an additional 266,587 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

SYK has been the topic of several research analyst reports. Citigroup reiterated a "buy" rating and issued a $450.00 price objective on shares of Stryker in a research note on Wednesday, February 26th. Canaccord Genuity Group upped their price target on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Stifel Nicolaus lifted their price objective on Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a report on Wednesday, January 29th. Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 price objective on shares of Stryker in a report on Friday, March 21st. Finally, JMP Securities reiterated a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $423.05.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Stryker Price Performance

Shares of NYSE:SYK traded up $1.81 on Monday, hitting $352.09. The company's stock had a trading volume of 329,900 shares, compared to its average volume of 1,355,493. The company has a market capitalization of $134.39 billion, a PE ratio of 45.37, a PEG ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a 50-day simple moving average of $375.54 and a 200 day simple moving average of $373.63. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the company earned $3.46 EPS. Sell-side analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.95%. Stryker's dividend payout ratio is presently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.